Pharmaceutical company Enzon may hive off its entire specialty drugs division, including a manufacturing facility in Indianapolis, US, in the face of pressure from shareholder Carl Icahn.
Cambrex posted a 5 per cent hike in revenues in the second quarter, helped by its shift into contract controlled substance manufacture, although without favourable currency effects sales would have slipped back 2.6 per cent.
The gulf in rates of growth between emerging and established markets in the biotech active pharmaceutical ingredient (API) sector has been highlighted in a new report from the Chemical Pharmaceutical Generic Association (CPA).
in-PharmaTechnologist.com's round-up of developments in the pharmaceutical manufacturing space features news of TGA approval for Capsugel’s plant, Spain’s first therapeutic protein plant and Isogen setting up in Delaware.
The US Food and Drug Administration (FDA) is seeking feedback from the pharmaceutical industry to develop the recommendations of the Nanotechnology Task Force.
Kendle has posted a sprightly 30 per cent increase in service revenues in the second quarter, bringing in $127m, well ahead of forecasts and providing further evidence of the buoyancy of the contract research market.
Charles River Laboratories saw its operating income advance 16 per cent to $77m in the second quarter on strong demand for its research services division, and also announced a $53m deal to buy a German contract service organisation.
Outsourcing-Pharma.com presents its periodic round-up of new appointments, employment moves and personnel news in the pharmaceutical contract services sector.
University of York, UK, spin-out Paraytec, has published new results that extend the use of its ActiPix UV area imaging detector to applications in enzyme assays and protein sizing.
Integrated DNA Technologies (IDT) has completed the expansion of its European production facility, enabling the company to supply its European customers faster than ever before.
Bruker recorded a 31 per cent increase in revenue for the second quarter, marking a strong start after it acquired its affiliated Bruker BioSpin in February for $914m.
Veeco Instruments returned to profitability with the company’s ‘best quarterly performance in two years’ even though its metrology unit struggled due to weakness in the semiconductor market.
TTP LabTech has launched the RAPid 4 - a flow-based biosensor that can conduct real-time label-free molecular interaction analysis in buffered solutions and in complex biological mixtures.
Eli Lilly took a giant leap down the outsourcing road yesterday with the sale of a major R&D facility to contract research organisation Covance and the forging of additional agreement with Quintiles and i3.
US packaging specialist West Pharmaceutical Services has carried the earnings momentum it generated in the first three months of the year through to the second quarter.
Generic drugmaker Actavis Totowa has voluntarily recalled all drugs produced at its Little Falls, New Jersey manufacturing facility after an FDA inspection uncovered several breaches of current GMP codes.
US protein manufacture and development services provider American Peptide Company (APC) says that its parent company, Ito Life Sciences (ILS), is to be acquired by fellow Japanese firm Otsuka Chemical.
Lonza hopes that the new business it has set up in China will help cement its position as a leading provider of services to the country’s pharmaceutical manufacturing sector.
Gerresheimer has formally started the process to sell off its technical plastics business, keeping its promise to exit non-core businesses and focus on more lucrative sectors such as medical and pharmaceutical plastics.
Panellists serving on the FDA's advisory committees will have stricter limits on their financial ties to industry under a raft of reforms announced by the agency yesterday.
Pharmaceutical commercialization services specialist inVentive Health is to buy fellow New Jersey-based healthcare research firm Patient Marketing Group (PMG) for an all cash payment of $14.5m (€9.4m).
The lacklustre performance of Millipore’s bioprocess division has continued into the second quarter of the year with revenues reaching $229.8m (€147m) up just one per cent on the comparable 2007 quarter.
ICON has introduced an electronic Patient Recorded Outcomes (ePRO) module that could slash weeks off the time it takes to implement the technology in clinical trials.
in-PharmaTechnologist.com's round-up of developments in the fight against counterfeiting, including Movianto’s ‘DNA’ coding, e-pedigree packaging machinery and a new handheld device.
Bioprocessing specialist Sartorius Stedim Biotech’s (SSB) net profit for the first half of 2008 rose by 3.5 per cent in comparison with last year, although the company continues to face difficulties in North America.
Harro Hofliger’s adoption of the FMEA-Med software will help the German machining specialist minimize risk during development operations, according to Canadian developer Dyadem.
Combined CMO and specialty pharmaceutical group Akorn hopes that deals signed this month with Bioniche Pharma and an as yet unidentified drugmaker will help its manufacturing division make up the ground lost in the last quarter.
PharmaNet has reported a stellar set of second-quarter results, reversing its year-earlier loss with a $2.2m profit that was driven by a good performance by the firm’s early-stage development business.
IT infrastructure and business process services firm Cognizant has cut back its full-year financial forecasts on signs that the downturn in the economy is starting to bite at some of its major clients, particularly those in the healthcare sector.
Invitrogen’s plans to buy Applied Biosystems (ABI) are on track with US antitrust regulators approving the deal and both firms achieving strong revenue growth.
Affymetrix slumped to an operating loss in the second quarter of 2008, reporting flat revenues and blaming a 30 per cent reduction in sales to the pharmaceutical sector.
Robert Friel’s tenure as CEO of PerkinElmer continued its strong start with the firm reporting a 21 per cent increase in second quarter revenues compared to the same period last year.
US Senator Sherrod Brown has fired off another broadside in his probe into pharmaceutical outsourcing, this time sending a request to Merck & Co “for further information on its heavy reliance on global outsourcing for the manufacture of pharmaceutical...
A new packaging artwork management system will help cost-sensitive generics producers cut launch times and make increased use of outsourcing, according to US developer Precise Data (PD).
US contract research giant Covance saw a strong performance across its divisions in the second quarter that lifted its revenues by 15 per cent to $462m.
US R&D organisation Draper Laboratory has unveiled plans to set up a new centre to develop and produce of its bioMEMS technology for therapeutic and healthcare applications.
The future of Eli Lilly's API manufacturing facility in Lafayette, Indiana has been thrown into doubt by the news the company is considering selling it.
In response to high customer demand, leading automated chemistry systems manufacturer Syrris is now offering to build custom-made laboratory reactor systems designed to meet individual customer needs.
Bio-Rad has published several application notes describing the use of its Profinity eXact protein expression system to obtain tag-free native proteins from a cell lysate in less than an hour.
in-PharmaTechnologist’s periodic round up of developments in the field of drug delivery includes BioDelivery initiating Phase I studies, success for Titan and a novel use for Viagra.
Ranbaxy’s CEO has confidently asserted that the US Food and Drug Administration’s (FDA) court action will be dropped in the near future and fired another warning shot at the “negative elements” he believes were behind the controversy.
FDA officials have impounded nearly $24m (€15.4m) worth of guaifenesin-containing timed-release (TR) cough and cold medicines made by US specialty drugmaker KV Pharmaceuticals.
Outsourcing-Pharma.com provides its periodic round-up of developments in the eClinical space, including a tough decision for Datatrak, news of a new contract for Medidata , a recruitment package from HMS and cardiac data certification for specialty CRO...
Like many of its peers in the contract clinical research sector, data management specialist Phase Forward put in another bumper financial performance in the second quarter headed by a 30 per cent hike in revenues to $41m.
Contract manufacturer Nectar Lifesciences is to invest around RS 6bn ($141m) in a new bulk drug and pharmaceutical intermediate manufacturing facility in India's northern Punjab state.
Patients who took Roche’s antiviral Viracept (nelfinavir) from batches contaminated with ethyl mesilate do not have an increased risk of developing cancer, according to the EMEA.